ArticleFrontiers in medicine2026
Association between the C-reactive protein-triglyceride-glucose index and major adverse cardiovascular events in patients undergoing percutaneous coronary intervention.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The interaction between inflammation and insulin resistance is a key driver of atherosclerosis. However, the combined effect of C-reactive protein (CRP) and triglyceride-glucose index (TyG) on the risk of major adverse cardiovascular events (MACEs) remains unclear. This study aims to evaluate the association between the C-reactive protein-triglyceride-glucose index (CTI) and major adverse cardiovascular events following percutaneous coronary intervention (PCI). Methods: Retrospective data from 2,610 patients who underwent PCI were collected. The association between the CTI and the risk of adverse outcomes was evaluated using survival analysis, Cox regression, restricted cubic splines (RCS), time-dependent receiver operating characteristic (ROC) curves, subgroup analysis, and sensitivity analysis. Results: During the follow-up period, 459 participants experienced MACEs. The incidence of adverse outcomes differed significantly across CTI levels, and Cox regression analysis indicated that CTI is an independent predictor. RCS analysis showed a non-linear relationship between CTI and the primary endpoint, and a linear relationship with the secondary endpoint. CTI demonstrated good predictive ability for adverse outcomes, and the results were validated by subgroup and sensitivity analyses, confirming their stability. Conclusion: Pre-PCI CTI levels are significantly associated with adverse outcome.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.